NASDAQ · Financial Statements

Caris Life Sciences, Inc. (CAI) Financial Statements

$32.00 NASDAQ: CAI Market Cap $9.05B

Caris Life Sciences, Inc. most recently reported annual revenue of $812.0M, a net loss of $538.0M. Revenue grew at an average annual rate of 14.3% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Caris Life Sciences, Inc.: Revenue rose from $250.0M in 2015 to $812.0M in 2025, a change of +224.8% over 9 years; net profit was positive in 6 of 10 reported years; operating margin moved from 27.3% to 5.6%, a shift of -21.7 percentage points; the most recent year shows a net loss of $538.0M.

Income Statement — 10 Years (USD millions)

Metric2015201620172018201920202022202320242025
Revenue$250.0M$294.0M$348.0M$432.0M$417.0M$294.0M$258.0M$306.0M$412.0M$812.0M
Operating Expenses$182.0M$228.0M$243.0M$283.0M$286.0M$155.0M$574.0M$626.0M$669.0M$767.0M
Operating Profit$68.0M$66.0M$106.0M$149.0M$130.0M$139.0M$-316.0M$-320.0M$-257.0M$45.0M
Operating Margin27.3%22.4%30.3%34.4%31.3%47.3%-122.2%-104.4%-62.4%5.6%
Other Income$-37.0M$-56.0M$-48.0M$-67.0M$0$-110.0M$-5.0M$-22.0M$-25.0M$-113.0M
Interest$36.0M$43.0M$53.0M$78.0M$79.0M$62.0M$27.0M$32.0M$50.0M$57.0M
Depreciation$114.0M$107.0M$113.0M$123.0M$114.0M$111.0M$48.0M$49.0M$49.0M$23.0M
Profit Before Tax$31.0M$10.0M$57.0M$81.0M$55.0M$30.0M$-321.0M$-341.0M$-282.0M$-68.0M
Tax$13.6M$38.9M$-26.0M$3.5M$7.6M$6.1M$0$0$0$-690.1M
Net Profit$27.0M$6.0M$72.0M$79.0M$31.0M$28.0M$-321.0M$-341.0M$-282.0M$-538.0M
EPS$1.28$0.31$3.68$3.97$1.72$1.55$-1.57$-1.82$-2.70$-1.86
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricJun '21Sep '21Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$86.0M$101.0M$81.0M$100.0M$102.0M$130.0M$121.0M$181.0M$217.0M$293.0M$216.0M$264.0M
Operating Expenses$35.0M$34.0M$173.0M$33.0M$162.0M$167.0M$179.0M$163.0M$184.0M$204.0M$211.0M$237.0M
Operating Profit$51.0M$66.0M$-92.0M$67.0M$-61.0M$-37.0M$-58.0M$18.0M$33.0M$88.0M$5.0M$27.0M
Operating Margin59.3%65.9%-114.3%67.0%-59.9%-28.5%-47.9%9.9%15.1%30.2%2.4%10.2%
Interest$11.0M$0$9.0M$14.0M$14.0M$13.0M$13.0M$19.0M$14.0M$11.0M$13.0M$9.0M
Profit Before Tax$40.0M$55.0M$-111.0M$-66.0M$-68.0M$-37.0M$-103.0M$-72.0M$24.0M$82.0M$-1.0M$-1.0M
Tax$4.7M$6.7M$0$0$0$0$0$0$0$0$20.8M$-3.8M
Net Profit$38.0M$51.0M$-111.0M$-66.0M$-68.0M$-37.0M$-103.0M$-72.0M$24.0M$82.0M$-1.0M$-1.0M
EPS$2.04$2.92$-0.53$-0.35$-0.33$-0.22$-0.40$-1.87$0.08$0.28$0.00$0.00

Over the 10 years reported for Caris Life Sciences, Inc., borrowings decreased from $1.4B in 2015 to $379.0M in 2025, cash stood at $798.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 7.86 times.

Balance Sheet — 10 Years (USD millions)

Metric2015201620172018201920202022202320242025
Total Assets$2.0B$2.1B$2.4B$3.0B$2.9B$2.6B$717.0M$413.0M$344.0M$1.1B
Current Assets$144.0M$135.0M$140.0M$220.0M$499.0M$215.0M$516.0M$243.0M$216.0M$998.0M
Cash$53.0M$46.0M$35.0M$45.0M$46.0M$54.0M$107.0M$56.0M$64.0M$798.0M
Inventory$0$0$0$0$0$0$47.0M$49.0M$40.0M$0
Receivables$76.0M$84.0M$101.0M$172.0M$160.0M$144.0M$40.0M$55.0M$88.0M$112.0M
Fixed Assets$1.7B$1.8B$2.0B$2.3B$1.8B$1.8B$138.0M$148.0M$103.0M$63.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$103.0M$101.0M$277.0M$550.0M$495.0M$79.0M$302.0M$65.0M$2.0M$2.0M
Other Assets$3.0M$16.0M$16.0M$16.0M$16.0M$0$19.0M$19.0M$19.0M$19.0M
Total Liabilities$1.5B$1.6B$1.9B$2.3B$2.2B$1.9B$2.4B$2.6B$2.8B$548.0M
Current Liabilities$218.0M$164.0M$260.0M$426.0M$287.0M$320.0M$137.0M$95.0M$165.0M$127.0M
Borrowings$1.4B$1.5B$1.7B$2.2B$2.1B$1.7B$271.0M$217.0M$424.0M$379.0M
Other Liabilities$94.0M$122.0M$164.0M$152.0M$110.0M$165.0M$2.1B$2.3B$2.4B$169.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$460.0M$458.0M$564.0M$701.0M$693.0M$702.0M$-1.7B$-2.1B$-2.5B$577.0M

For Caris Life Sciences, Inc., operating cash flow was positive in 7 of 10 reported years; free cash flow in the latest year was $67.0M; free cash flow was positive in 2 of 10 years; financing activities used $19.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2015201620172018201920202022202320242025
Operating Cash Flow$147.0M$129.0M$155.0M$180.0M$254.0M$277.0M$-286.0M$-276.0M$-245.0M$83.0M
Investing Cash Flow$-695.0M$-433.0M$-914.0M$-1.5B$-591.0M$-253.0M$-325.0M$192.0M$44.0M$-33.0M
Financing Cash Flow$144.0M$37.0M$246.0M$475.0M$-134.0M$-240.0M$11.0M$0$0$-19.0M
Net Cash Flow$-1.0M$-6.0M$-11.0M$29.0M$-3.0M$-7.0M$-558.0M$-51.0M$8.0M$732.0M
Free Cash Flow$-242.0M$-122.0M$-347.0M$-633.0M$-65.0M$58.0M$-328.0M$-298.0M$-254.0M$67.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.30
EV / EBITDA48.37
FCF Yield1.71%
Quick Ratio4.88
Interest Coverage3.27
Return 1Y-4.37%
Return 3Y—
Return 5Y—

Caris Life Sciences, Inc. (CAI) financials — frequently asked questions

What is Caris Life Sciences, Inc.'s annual revenue?

Caris Life Sciences, Inc. (CAI) reported annual revenue of $812.0M in its most recent fiscal year.

What is Caris Life Sciences, Inc.'s net profit?

Caris Life Sciences, Inc. (CAI) reported a net loss of $538.0M in its most recent fiscal year.

What is CAI EV/EBITDA?

Caris Life Sciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 48.37.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
CAI Overview CAI Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.